Novo Nordisk's Wegovy pill exceeds expectations, gains edge in competition with Lilly

The Wegovy pill surpassing expectations indicates that Novo Nordisk is gaining a competitive advantage over Lilly in the obesity market and could lend positive momentum to the stock in the short term. The price rose 3.97% in the last 24 hours, closing at 40.22, just below the SMA20 (40.27); a break above this resistance could confirm the upward direction. RSI14 is at 57, far from overbought territory, meaning there is room for the move to continue. However, MACD (0.27) is below its signal line (0.35) and a clear bullish crossover has not yet formed, which calls for caution. Although the news flow is supportive, technical indicators are giving mixed signals, so I keep confidence at a moderate level.

The news headline concerns Novo Nordisk and Eli Lilly and is not directly related to GOOGL's core operations; therefore, its impact on GOOGL is likely limited and indirect. The technical picture is weak: the price is slightly below the SMA20 and significantly below the SMA50, the RSI at 36 is weak but close to oversold territory, and the MACD is in negative territory but above its signal line. No news-driven direction is expected in the short term; rather, the existing weak trend and possible bargain hunting may be decisive. A neutral assessment therefore appears appropriate.

Novo Nordisk's Wegovy pill exceeding expectations could weaken LLY's competitive position in the obesity/diabetes market in the short term and create selling pressure on the stock. On the technical side, the price is trading just below the SMA20 (1415.8) and below the MACD signal line, indicating weakening momentum. However, the RSI is around 58 in neutral territory and the medium-term trend above the SMA50 (1351) is still intact, suggesting the decline may be limited. There is also profit-taking risk after a 3.3% rise in 24 hours. Overall, although the news flow is negative, I maintain moderate confidence as technical indicators do not signal oversold conditions.